The stock won't stay down forever.Pharmaceutical giant Pfizer (PFE -1.43%) has been in a bit of a freefall since early 2022, with shares down by 46%. Pfizer's revenue and earnings dropped off a cliff along with its coronavirus-related results as the pandemic started fading, which explains its poor performance over the past 18 months. However, there are clues that Pfizer is starting to make a comeback. That's an important takeaway from Pfizer's second-quarter results. Let's dig in. Revenue is finally moving ...